Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.

@article{Anand2004LongtermEO,
  title={Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.},
  author={Inder S. Anand and John P. McMurray and Jay N. Cohn and Marvin A. Konstam and Thomas Notter and Kurt Quitzau and Frank T. Ruschitzka and Thomas Felix L{\"u}scher},
  journal={Lancet},
  year={2004},
  volume={364 9431},
  pages={347-54}
}
BACKGROUND Endothelin-receptor blockade provides haemodynamic benefit in experimental and clinical heart failure. We aimed to measure the effects of long-term endothelin-blockade on left-ventricular (LV) remodelling and clinical outcomes in patients with chronic heart failure. METHODS 642 patients with chronic heart failure were assigned the oral endothelin(A)-antagonist darusentan at 10, 25, 50, 100, or 300 mg daily or placebo for 24 weeks in addition to standard therapy in a randomised… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 104 extracted citations

Similar Papers

Loading similar papers…